Zevra Therapeutics Reports Q3 Earnings Beat on Revenue and EPS
Zevra Therapeutics (ZVRA) reported third-quarter financial results that exceeded analyst expectations for both earnings per share and revenue. The company posted a GAAP EPS of $0.26, surpassing estimates by $0.11, while total revenue reached $37.8 million, representing a 44.8% increase year-over-year. Operating expenses for the quarter were reported at $24.1 million, which includes $2.7 million in non-cash stock compensation. The strong top-line growth and earnings beat suggest positive momentum for the company's commercial operations.
Tickers: $ZVRA
Topics: earnings beat GAAP EPS revenue growth